Published in Hepatitis Weekly, December 15th, 1997
There is increasing evidence that longer treatment boosts sustained responses to interferon, but the cost-effectiveness of a longer treatment schedule is a hotly debated topic.
In this study, researcher M. Buti and colleagues evaluated the cost-effectiveness of the treatment of mild chronic hepatitis C with different schedules of alpha interferon (IFN) in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.